Cargando…

Acute and late toxicity in prostate cancer patients treated by dose escalated intensity modulated radiation therapy and organ tracking

BACKGROUND: To report acute and late toxicity in prostate cancer patients treated by dose escalated intensity-modulated radiation therapy (IMRT) and organ tracking. METHODS: From 06/2004 to 12/2005 39 men were treated by 80 Gy IMRT along with organ tracking. Median age was 69 years, risk of recurren...

Descripción completa

Detalles Bibliográficos
Autores principales: Ghadjar, Pirus, Vock, Jacqueline, Vetterli, Daniel, Manser, Peter, Bigler, Roland, Tille, Jan, Madlung, Axel, Behrensmeier, Frank, Mini, Roberto, Aebersold, Daniel M
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2613141/
https://www.ncbi.nlm.nih.gov/pubmed/18937833
http://dx.doi.org/10.1186/1748-717X-3-35
_version_ 1782163157585756160
author Ghadjar, Pirus
Vock, Jacqueline
Vetterli, Daniel
Manser, Peter
Bigler, Roland
Tille, Jan
Madlung, Axel
Behrensmeier, Frank
Mini, Roberto
Aebersold, Daniel M
author_facet Ghadjar, Pirus
Vock, Jacqueline
Vetterli, Daniel
Manser, Peter
Bigler, Roland
Tille, Jan
Madlung, Axel
Behrensmeier, Frank
Mini, Roberto
Aebersold, Daniel M
author_sort Ghadjar, Pirus
collection PubMed
description BACKGROUND: To report acute and late toxicity in prostate cancer patients treated by dose escalated intensity-modulated radiation therapy (IMRT) and organ tracking. METHODS: From 06/2004 to 12/2005 39 men were treated by 80 Gy IMRT along with organ tracking. Median age was 69 years, risk of recurrence was low 18%, intermediate 21% and high in 61% patients. Hormone therapy (HT) was received by 74% of patients. Toxicity was scored according to the CTC scale version 3.0. Median follow-up (FU) was 29 months. RESULTS: Acute and maximal late grade 2 gastrointestinal (GI) toxicity was 3% and 8%, late grade 2 GI toxicity dropped to 0% at the end of FU. No acute or late grade 3 GI toxicity was observed. Grade 2 and 3 pre-treatment genitourinary (GU) morbidity (PGUM) was 20% and 5%. Acute and maximal late grade 2 GU toxicity was 56% and 28% and late grade 2 GU toxicity decreased to 15% of patients at the end of FU. Acute and maximal late grade 3 GU toxicity was 8% and 3%, respectively. Decreased late ≥ grade 2 GU toxicity free survival was associated with higher age (P = .025), absence of HT (P = .016) and higher PGUM (P < .001). DISCUSSION: GI toxicity rates after IMRT and organ tracking are excellent, GU toxicity rates are strongly related to PGUM.
format Text
id pubmed-2613141
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-26131412009-01-01 Acute and late toxicity in prostate cancer patients treated by dose escalated intensity modulated radiation therapy and organ tracking Ghadjar, Pirus Vock, Jacqueline Vetterli, Daniel Manser, Peter Bigler, Roland Tille, Jan Madlung, Axel Behrensmeier, Frank Mini, Roberto Aebersold, Daniel M Radiat Oncol Research BACKGROUND: To report acute and late toxicity in prostate cancer patients treated by dose escalated intensity-modulated radiation therapy (IMRT) and organ tracking. METHODS: From 06/2004 to 12/2005 39 men were treated by 80 Gy IMRT along with organ tracking. Median age was 69 years, risk of recurrence was low 18%, intermediate 21% and high in 61% patients. Hormone therapy (HT) was received by 74% of patients. Toxicity was scored according to the CTC scale version 3.0. Median follow-up (FU) was 29 months. RESULTS: Acute and maximal late grade 2 gastrointestinal (GI) toxicity was 3% and 8%, late grade 2 GI toxicity dropped to 0% at the end of FU. No acute or late grade 3 GI toxicity was observed. Grade 2 and 3 pre-treatment genitourinary (GU) morbidity (PGUM) was 20% and 5%. Acute and maximal late grade 2 GU toxicity was 56% and 28% and late grade 2 GU toxicity decreased to 15% of patients at the end of FU. Acute and maximal late grade 3 GU toxicity was 8% and 3%, respectively. Decreased late ≥ grade 2 GU toxicity free survival was associated with higher age (P = .025), absence of HT (P = .016) and higher PGUM (P < .001). DISCUSSION: GI toxicity rates after IMRT and organ tracking are excellent, GU toxicity rates are strongly related to PGUM. BioMed Central 2008-10-20 /pmc/articles/PMC2613141/ /pubmed/18937833 http://dx.doi.org/10.1186/1748-717X-3-35 Text en Copyright © 2008 Ghadjar et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Ghadjar, Pirus
Vock, Jacqueline
Vetterli, Daniel
Manser, Peter
Bigler, Roland
Tille, Jan
Madlung, Axel
Behrensmeier, Frank
Mini, Roberto
Aebersold, Daniel M
Acute and late toxicity in prostate cancer patients treated by dose escalated intensity modulated radiation therapy and organ tracking
title Acute and late toxicity in prostate cancer patients treated by dose escalated intensity modulated radiation therapy and organ tracking
title_full Acute and late toxicity in prostate cancer patients treated by dose escalated intensity modulated radiation therapy and organ tracking
title_fullStr Acute and late toxicity in prostate cancer patients treated by dose escalated intensity modulated radiation therapy and organ tracking
title_full_unstemmed Acute and late toxicity in prostate cancer patients treated by dose escalated intensity modulated radiation therapy and organ tracking
title_short Acute and late toxicity in prostate cancer patients treated by dose escalated intensity modulated radiation therapy and organ tracking
title_sort acute and late toxicity in prostate cancer patients treated by dose escalated intensity modulated radiation therapy and organ tracking
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2613141/
https://www.ncbi.nlm.nih.gov/pubmed/18937833
http://dx.doi.org/10.1186/1748-717X-3-35
work_keys_str_mv AT ghadjarpirus acuteandlatetoxicityinprostatecancerpatientstreatedbydoseescalatedintensitymodulatedradiationtherapyandorgantracking
AT vockjacqueline acuteandlatetoxicityinprostatecancerpatientstreatedbydoseescalatedintensitymodulatedradiationtherapyandorgantracking
AT vetterlidaniel acuteandlatetoxicityinprostatecancerpatientstreatedbydoseescalatedintensitymodulatedradiationtherapyandorgantracking
AT manserpeter acuteandlatetoxicityinprostatecancerpatientstreatedbydoseescalatedintensitymodulatedradiationtherapyandorgantracking
AT biglerroland acuteandlatetoxicityinprostatecancerpatientstreatedbydoseescalatedintensitymodulatedradiationtherapyandorgantracking
AT tillejan acuteandlatetoxicityinprostatecancerpatientstreatedbydoseescalatedintensitymodulatedradiationtherapyandorgantracking
AT madlungaxel acuteandlatetoxicityinprostatecancerpatientstreatedbydoseescalatedintensitymodulatedradiationtherapyandorgantracking
AT behrensmeierfrank acuteandlatetoxicityinprostatecancerpatientstreatedbydoseescalatedintensitymodulatedradiationtherapyandorgantracking
AT miniroberto acuteandlatetoxicityinprostatecancerpatientstreatedbydoseescalatedintensitymodulatedradiationtherapyandorgantracking
AT aebersolddanielm acuteandlatetoxicityinprostatecancerpatientstreatedbydoseescalatedintensitymodulatedradiationtherapyandorgantracking